Abstract
Our aim is to assess the incidence of second cancer in long-time surviving primary mediastinal B-cell lymphoma (PMBCL) patients treated with combined radiochemoimmunotherapy (standard methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin with rituximab and mediastinal radiation therapy at a dose of 30 to 36 Gy). For this purpose, 92 points were evaluated. After a median overall survival of 137 months (range 76-212), we recorded second cancer in 3 of 80 long-surviving patients (3.75%) with cumulative incidence of 3.47% at 15 years and 11% at 17 years, with a 17-year second cancer-free survival of 82%. We observed 2 papillary thyroid cancers with a standardized incidence ratio (SIR) of 7.97 and an absolute excess risk (AER) of 17. 84 and 1 acute myeloid leukemia (AML) with an SIR of 66.53 and an AER of 10.05. No breast cancer occurred. Although we should take into account the limits of the proposed statistical analysis, combined modality treatment was related to a significant SIR and AER for thyroid cancer and acute myeloid leukemia.
| Original language | English |
|---|---|
| Pages (from-to) | 554-560 |
| Number of pages | 7 |
| Journal | Hematological Oncology |
| Volume | 35 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Dec 1 2017 |
Fingerprint
Keywords
- lymphoma
- myeloid leukemias
- radiotherapy
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy : Results from a monoinstitutional cohort analysis of long-term survivors. / De Sanctis, Vitaliana; Alfò, Marco; Di Rocco, Alice; Ansuinelli, Michela; Russo, Eleonora; Osti, Mattia F.; Valeriani, Maurizio; Minniti, Giuseppe; Grapulin, Lavinia; Musio, Daniela; Bracci, Stefano; Spagnoli, Alessandra; Moleti, Maria Luisa; Tombolini, Vincenzo; Martelli, Maurizio.
In: Hematological Oncology, Vol. 35, No. 4, 01.12.2017, p. 554-560.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy
T2 - Results from a monoinstitutional cohort analysis of long-term survivors
AU - De Sanctis, Vitaliana
AU - Alfò, Marco
AU - Di Rocco, Alice
AU - Ansuinelli, Michela
AU - Russo, Eleonora
AU - Osti, Mattia F.
AU - Valeriani, Maurizio
AU - Minniti, Giuseppe
AU - Grapulin, Lavinia
AU - Musio, Daniela
AU - Bracci, Stefano
AU - Spagnoli, Alessandra
AU - Moleti, Maria Luisa
AU - Tombolini, Vincenzo
AU - Martelli, Maurizio
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Our aim is to assess the incidence of second cancer in long-time surviving primary mediastinal B-cell lymphoma (PMBCL) patients treated with combined radiochemoimmunotherapy (standard methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin with rituximab and mediastinal radiation therapy at a dose of 30 to 36 Gy). For this purpose, 92 points were evaluated. After a median overall survival of 137 months (range 76-212), we recorded second cancer in 3 of 80 long-surviving patients (3.75%) with cumulative incidence of 3.47% at 15 years and 11% at 17 years, with a 17-year second cancer-free survival of 82%. We observed 2 papillary thyroid cancers with a standardized incidence ratio (SIR) of 7.97 and an absolute excess risk (AER) of 17. 84 and 1 acute myeloid leukemia (AML) with an SIR of 66.53 and an AER of 10.05. No breast cancer occurred. Although we should take into account the limits of the proposed statistical analysis, combined modality treatment was related to a significant SIR and AER for thyroid cancer and acute myeloid leukemia.
AB - Our aim is to assess the incidence of second cancer in long-time surviving primary mediastinal B-cell lymphoma (PMBCL) patients treated with combined radiochemoimmunotherapy (standard methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin with rituximab and mediastinal radiation therapy at a dose of 30 to 36 Gy). For this purpose, 92 points were evaluated. After a median overall survival of 137 months (range 76-212), we recorded second cancer in 3 of 80 long-surviving patients (3.75%) with cumulative incidence of 3.47% at 15 years and 11% at 17 years, with a 17-year second cancer-free survival of 82%. We observed 2 papillary thyroid cancers with a standardized incidence ratio (SIR) of 7.97 and an absolute excess risk (AER) of 17. 84 and 1 acute myeloid leukemia (AML) with an SIR of 66.53 and an AER of 10.05. No breast cancer occurred. Although we should take into account the limits of the proposed statistical analysis, combined modality treatment was related to a significant SIR and AER for thyroid cancer and acute myeloid leukemia.
KW - lymphoma
KW - myeloid leukemias
KW - radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85010775214&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85010775214&partnerID=8YFLogxK
U2 - 10.1002/hon.2377
DO - 10.1002/hon.2377
M3 - Article
VL - 35
SP - 554
EP - 560
JO - Hematological Oncology
JF - Hematological Oncology
SN - 0278-0232
IS - 4
ER -